Engineered atenolol-glycoconjugates to target H9c2 cardiomyocyte cell lines

• Autorzy: Smita Tukaram Kumbhar , Manish Sudesh Bhatia , Shitalkumar Shivgonda Patil
• Języki publikacji: EN

Abstrakty

EN

Background: One of the most important fields of biomedical engineering study nowadays is targeted drug delivery to specific cells. A drug's therapeutic efficacy can be improved and optimised by tightly targeting it to a pathophysiologically essential tissue architecture. The goal of this research is to develop saccharide conjugates for the targeted delivery of Atenolol, a -blocker. Methods: Galactose (monosaccharide), pectin (polysaccharide), and chitosan were chosen as the saccharides (polysaccharide). By grafting Atenolol with the modified saccharides, the conjugates were created. Spectroscopic and thermal studies were used to describe the chemically changed saccharides conjugates. H9c2 cell lines were used to conduct drug release research and cellular uptake studies. To investigate cytotoxicity, a brine shrimp lethality test was done. Results: The outcomes exhibit that Atenolol-modified saccharide conjugates can productively convey the medication to the target. Conclusion: It can be inferred that the improvement of saccharide-drug conjugates can be a compelling methodology for targeting cardiovascular medication.

Słowa kluczowe

PL

Zdrowie; Biotechnologia; Polimery

EN

Health; Biotechnology; Polymers

• Czasopismo: Acta Innovations
• Rocznik: 2022
• Numer: nr 43
• Strony: 36-43

Twórcy

autor

Smita Tukaram Kumbhar

• Department of Pharmaceutical Chemistry, DSTS Mandal's College of Pharmacy Solapur, India

autor

Manish Sudesh Bhatia

• Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy Kolhapur, India

autor

Shitalkumar Shivgonda Patil

• Department of Pharmaceutics, Ashokrao Mane College of Pharmacy Peth Vadgaon, India

Bibliografia

• C. Fan, J. Joshi, F. Li, B. Xu, M. Khan, J. Yang, W. Zhu, Nanoparticle-mediated drug delivery for treatment of ischemic heart disease, "Frontiers in Bioengineering and Biotechnology", 8 (2020). https://doi.org/10.3389/fbioe.2020.00687.
• F. Ding, Y. Zhang, Biomedical applications of glycoconjugates, "Mini-Reviews in Medicinal Chemistry", 18 (2018) 1508-1523. https://doi.org/10.2174/1389557518666180518083427.
• T. Ben-Mordechai, D. Kain, R. Holbova, N. Landa, L. Levin, I. Elron-Gross, Y. Glucksam-Galnoy, M.S. Feinberg, R. Margalit, J. Leor, Targeting and modulating infarct macrophages with hemin formulated in designed lipid-based particles improves cardiac remodeling and function, "Journal of Controlled Release", 257 (2017) 21-31. https://doi.org/10.1016/j.jconrel.2017.01.001.
• K. Sztandera, P. Działak, M. Marcinkowska, M. Stańczyk, M. Gorzkiewicz, A. Janaszewska, B. Klajnert-Maculewicz, Sugar modification enhances cytotoxic activity of PAMAM-doxorubicin conjugate in glucose-deprived MCF-7 cells - possible role of GLUT1 transporter, "Pharmaceutical Research", 36 (2019) 140. https://doi.org/10.1007/s11095-019-2673-9.
• B. Thomas, K.C. Yan, X.L. Hu, M. Donnier-Maréchal, G. Chen, X.P. He, S. Vidal, Fluorescent glycoconjugates and their applications, "Chemical Society Reviews", 49 (2020) 593-641. https://doi.org/10.1039/C8CS00118A.
• L. Kou, Q. Yao, H. Zhang, M. Chu, Y.D. Bhutia, R. Chen, V. Ganapathy, Transporter-targeted nano-sized vehicles for enhanced and site-specific drug delivery, "Cancers" (Basel). 12 (2020) 2837. https://doi.org/10.3390/cancers12102837.
• M. Cheraghi, B. Negahdari, H. Daraee, A. Eatemadi, Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review, "Biomedicine & Pharmacotherapy", 86 (2017) 316-323. https://doi.org/10.1016/j.biopha.2016.12.009.
• S. Manandhar, E. Sjöholm, J. Bobacka, J.M. Rosenholm, K.K. Bansal, Polymer-drug conjugates as nanotheranostic agents, "Journal of Nanotheranostics", 2 (2021) 63-81. https://doi.org/10.3390/jnt2010005.
• Y. Ding, A. Zhao, T. Liu, Y. Wang, Y. Gao, J. Li, P. Yang, An injectable nanocomposite hydrogel for potential application of vascularization and tissue repair, "Annals of Biomedical Engineering", 48 (2020) 1511-1523. https://doi.org/10.1007/s10439-020-02471-7.
• S.T. Kumbhar, S.S. Patil, M.S. Bhatia, In silico design and pharmacological evaluation of conjugates of atenolol with modified saccharide for cardiovascular targeting, "Glycoconjugate Journal", 38 (2021) 261-271. https://doi.org/10.1007/s10719-021-09983-x.
• S.T. Kumbhar, S.S. Patil, M.S. Bhatia, Synthesis, characterization, in silico analysis, and pharmacological evaluation of metoprolol-modified saccharide conjugates for cardiovascular targeting, "Journal of Pharmaceutical Innovation", (2021). https://doi.org/10.1007/s12247-021-09574-1.
• R. Varela, I. Rauschert, G. Romanelli, A. Alberro, J.C. Benech, Hyperglycemia and hyperlipidemia can induce morphophysiological changes in rat cardiac cell line, "Biochemistry and Biophysics Reports", 26 (2021) 100983. https://doi.org/10.1016/j.bbrep.2021.100983.
• N. Lomis, S. Westfall, D. Shum-Tim, S. Prakash, Synthesis and characterization of peptide conjugated human serum albumin nanoparticles for targeted cardiac uptake and drug delivery, "PLoS One", 16 (2021) e0254305. https://doi.org/10.1371/journal.pone.0254305.
• A. V. Kuznetsov, S. Javadov, S. Sickinger, S. Frotschnig, M. Grimm, H9c2 and HL-1 cells demonstrate distinct features of energy metabolism, mitochondrial function and sensitivity to hypoxia-reoxygenation, "Biochimica et Biophysica Acta - Molecular Cell Research", 1853 (2015) 276-284. https://doi.org/10.1016/j.bbamcr.2014.11.015.
• J. Miao, L. Zhang, P. Gao, H. Zhao, X. Xie, J. Wang, Chitosan-based glycolipid conjugated siRNA delivery system for improving radiosensitivity of laryngocarcinoma, "Polymers" (Basel). 13 (2021) 2929. https://doi.org/10.3390/polym13172929.
• S.D. Jadhav, P.B. Choudhari, M.S. Bhatia, In silico design, synthesis, characterization and pharmacological evaluation of captopril conjugates in the treatment of renal fibrosis, "New Journal of Chemistry", 43 (2019) 504-513. https://doi.org/10.1039/C8NJ03836H.
• R. Pala, S. Pattnaik, S. Busi, S.M. Nauli, Nanomaterials as novel cardiovascular Ttheranostics, "Pharmaceutics", 13 (2021) 348. https://doi.org/10.3390/pharmaceutics13030348.

Identyfikatory

DOI

https://doi.org/10.32933/ActaInnovations.43.3